A new trading day began on Friday, with Editas Medicine Inc (NASDAQ: EDIT) stock price down -1.63% from the previous day of trading, before settling in for the closing price of $1.23. EDIT’s price has ranged from $1.16 to $11.58 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 101.57%. Meanwhile, its annual earnings per share averaged -31.45%. With a float of $81.78 million, this company’s outstanding shares have now reached $82.54 million.
Let’s determine the extent of company efficiency that accounts for 265 employees. In terms of profitability, gross margin is 90.46%, operating margin of -370.03%, and the pretax margin is -340.96%.
Editas Medicine Inc (EDIT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Editas Medicine Inc is 0.93%, while institutional ownership is 67.85%. The most recent insider transaction that took place on Dec 03 ’24, was worth 3,361. In this transaction CEO of this company sold 1,618 shares at a rate of $2.08, taking the stock ownership to the 312,106 shares. Before that another transaction happened on Dec 03 ’24, when Company’s EVP, CHIEF MEDICAL OFFICER sold 541 for $2.08, making the entire transaction worth $1,124. This insider now owns 133,354 shares in total.
Editas Medicine Inc (EDIT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.53 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -31.45% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 1.70% during the next five years compared to 2.88% growth over the previous five years of trading.
Editas Medicine Inc (NASDAQ: EDIT) Trading Performance Indicators
Here are Editas Medicine Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 3.75. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.56, a number that is poised to hit -0.34 in the next quarter and is forecasted to reach -1.42 in one year’s time.
Technical Analysis of Editas Medicine Inc (EDIT)
Looking closely at Editas Medicine Inc (NASDAQ: EDIT), its last 5-days average volume was 2.79 million, which is a jump from its year-to-date volume of 2.06 million. As of the previous 9 days, the stock’s Stochastic %D was 7.93%. Additionally, its Average True Range was 0.17.
During the past 100 days, Editas Medicine Inc’s (EDIT) raw stochastic average was set at 1.33%, which indicates a significant decrease from 4.14% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 118.31% in the past 14 days, which was higher than the 82.27% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.4366, while its 200-day Moving Average is $4.3950. However, in the short run, Editas Medicine Inc’s stock first resistance to watch stands at $1.3066. Second resistance stands at $1.4032. The third major resistance level sits at $1.4665. If the price goes on to break the first support level at $1.1467, it is likely to go to the next support level at $1.0834. Should the price break the second support level, the third support level stands at $0.9868.
Editas Medicine Inc (NASDAQ: EDIT) Key Stats
With a market capitalization of 98.26 million, the company has a total of 82,548K Shares Outstanding. Currently, annual sales are 78,120 K while annual income is -153,220 K. The company’s previous quarter sales were 60 K while its latest quarter income was -62,140 K.
